AONN-NSC 2018 - 9th Annual AONN Navigation & Survivorship Conference
Nov 15 - Nov 18, 2018 | DallasTXUS
LARVOL is not affiliated with 9th Annual AONN Navigation & Survivorship Conference and all trademarks, logos, and brand names are property of their respective owners
Showing 11 abstracts linked to Trials
CheckMate 227: Nivolumab + Ipilimumab vs Platinum-Doublet Chemotherapy as First-line Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) With High Tumor Mutational Burden (TMB)
Clinical development of the BCR-ABL1 tyrosine kinase inhibitor asciminib (ABL001) in chronic myeloid leukemia
Dabrafenib plus trametinib as adjuvant treatment of resected BRAF-mutant stage III melanoma: findings from the COMBI-AD trial analyzed based on AJCC 8 classification
Effect on health-related quality of life of adjuvant treatment with dabrafenib plus trametinib in patients with resected stage III BRAF-mutant melanoma
Efficacy, Safety, and Patient-Reported Outcomes of Postmenopausal Women With Advanced Breast Cancer Receiving Ribociclib + Fulvestrant: Results From MONALEESA-3
Four Years of Follow Up for Ibrutinib as First-Line Treatment of Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Long-Term Data and Oncology Nurses’ Experience with Adverse Event Management
Ibrutinib/Rituximab Versus Placebo/Rituximab in Waldenström’s Macroglobulinemia: A Randomized, Phase 3 Trial (iNNOVATE)
Using Technology in Practice to Improve Patient Symptoms: the eCO experience
Adverse event management during treatment with alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Efficacy, Safety, and Quality of Life in Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Treated With Ribociclib Combination Therapy: A Review of the Phase 3 MONALEESA-7 Trial
Health status in patients with small-cell lung cancer treated with nivolumab alone or combined with ipilimumab: CheckMate 032